Browse studies

Find your next paid study

379 recruiting studies matching your filters

ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI),…

High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular Risk

Estimated

~$10 – $8,750

Alnylam PharmaceuticalsNCT07181109

Phase 1

A Phase 2a Single Arm Open Label Safety and Efficacy Study of Telaglenastat Plus Standard of Care in Adults With Functional Class Ii-iii Precapillary Pulmonary Hypertension Across Wsph Groups 1-3

The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is …

Pulmonary Hypertension

Estimated

~$10 – $7,500

Chan, Stephen, MD, PhDNCT07223528

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adult…

Pulmonary Arterial Hypertension

Estimated

~$10 – $8,750

Insmed IncorporatedNCT07481981

Phase 4

A Phase IV Placebo-controlled Single Center Trial for Tirzepatide in Idiopathic Intracranial Hypertension Trial (TIIHT)

This will be a randomized, double-blind, parallel, placebo-controlled trial of 60 participants. The primary analysis will be a statistical comparison of the es…

Idiopathic Intracranial Hypertension (IIH)

Estimated

~$10 – $6,250

Duke UniversityNCT07191873

Observational

OBPM_PANDA2026: Pivotal Evaluation of the Performance and Safety of the Aktiia Periodic Optical Blood Pressure Monitoring (OBPM) Device at Wrist Against Double Auscultation: a Multicenter Prospective Clinical Study

This study, with N = 85 participants minimum over 3 visits spread over 7 days, has been designed to assess the accuracy and precision of the Blood Pressure and…

Disrupted Sleep in Somali Americans - Implications for Hypertension Risk

The aims of this study are to determine the types and severity of previously undiagnosed sleep deficiencies in otherwise healthy Somali Americans, apply a rese…

HypertensionSleep DisorderHealthy

Estimated

~$10 – $750

Mayo ClinicNCT05411029

Phase 2

A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pr…

Hypertension

Estimated

~$10 – $8,750

Alnylam PharmaceuticalsNCT07553442

Phase 3

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmo…

Pulmonary HypertensionInterstitial Lung DiseaseVascular Diseases+2 more

Estimated

~$10 – $8,750

Pulmovant, Inc.NCT07816185

Phase 1

Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH

Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background T…

Pulmonary Arterial Hypertension

Estimated

~$10 – $8,750

35Pharma IncNCT07143448

Phase 4

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the panc…

Morbid ObesityMetabolic SyndromeDiabetes Mellitus+2 more

Estimated

~$10 – $6,250

University of Missouri-ColumbiaNCT06132477

Observational

CROWN: Implementation of a Beauty Salon-Based Strategy for Blood Pressure Management Among Women

CROWN is a two-arm, cluster-randomized pilot trial testing the feasibility and preliminary efficacy of a salon-based cardiovascular intervention - training sty…

Hypertension

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07042386

Phase 2

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension second…

Hypertension, PulmonaryLung Diseases, Interstitial

Estimated

~$10 – $8,750

Tectonic Operating Company, Inc.NCT07473700